Boston Scientific Corp. (BSX) Tops Q2 EPS by 7c; Guides Q3 EPS Below, Reaffirms FY12
Tweet
Share
E-mailGet Alerts BSX Hot Sheet
Price: $43.34 -0.48%
Revenue Growth %: +2.6%
Financial Fact:
Cost of products sold: 594M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +2.6%
Financial Fact:
Cost of products sold: 594M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Boston Scientific Corp. (NYSE: BSX) reported Q2 EPS of $0.17, $0.07 better than the analyst estimate of $0.10. Revenue for the quarter came in at $1.83 billion versus the consensus estimate of $1.89 billion.
Boston Scientific Corp. sees Q3 2012 EPS of $0.14-$0.17, versus the consensus of $0.11. Boston Scientific Corp. sees Q3 2012 revenue of $1.725-$1.825 billion, versus the consensus of $1.83 billion.
Reaffirms FY12 outlook.
For earnings history and earnings-related data on Boston Scientific Corp. (BSX) click here.
Boston Scientific Corp. sees Q3 2012 EPS of $0.14-$0.17, versus the consensus of $0.11. Boston Scientific Corp. sees Q3 2012 revenue of $1.725-$1.825 billion, versus the consensus of $1.83 billion.
Reaffirms FY12 outlook.
For earnings history and earnings-related data on Boston Scientific Corp. (BSX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Kepler Cheuvreux Downgrades Volkswagen AG (VOW:GR) (VWAGY) to Hold
- UBS cuts KOSPI target by nearly 10% to reflect higher rates
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
